▍ Source/Cyber blue/medicine Rubik's Cube
▍ Finishing / Koharu
Stone medicine was listed for the first time, and Hengrui's ranking climbed
1
The ranking of TOP50 pharmaceutical companies was announced
Recently, PharmExec (American Pharmaceutical Manager Magazine) released the 2021 Global Pharmaceutical Companies TOP50 List. The list is mainly based on the sales revenue of prescription drugs in the 2020 fiscal year of each pharmaceutical company, and has been published for 21 consecutive years the top 50 list of global pharmaceutical companies, which has been recognized by the industry.
According to the combing, the top ten are Roche, Novartis, AbbVie, Johnson & Johnson, Bristol-Myers Squibb, Merck, Sanofi, Pfizer, GlaxoSmithKline, and Takeda. Compared with 2020, the rankings of Roche, Novartis, Bristol-Myers Squibb, Sanofi, GlaxoSmithKline and Takeda have not changed, AbbVie has changed from 8th to 3rd, Pfizer from 3rd to 8th, Johnson & Johnson from 6th to 4th, and Merck from 4th to 6th.
This time, there are 5 Chinese pharmaceutical companies on the list, namely: Yunnan Baiyao, Hengrui Pharmaceutical, China Biopharmaceutical, Shanghai Pharmaceutical, CSPC Pharmaceutical Group, the largest number in history.
Three of these 50 companies are new faces, in addition to CSPC, there are HuiZhi (19th) formed by the merger of Mylan and Pfizer Puqiang and the German STADA Arzneimittel (50th).
2
Five Chinese pharmaceutical companies made the list
In 2019, the top 50 list of global pharmaceutical companies appeared for the first time in the figure of Chinese pharmaceutical companies, two on the list, reaching four in 2020, and by 2021, a total of 5 Pharmaceutical companies in China were selected, and the number increased year by year.
The companies on the list are Yunnan Baiyao (No. 34, US$4.741 billion), Hengrui Pharmaceutical (No. 38, US$4.203 billion), China Biopharmaceutical (No. 40, US$3.893 billion), Shanghai Pharmaceutical (42nd, US$3.585 billion) and CSPC Pharmaceutical Group (44th, US$3.242 billion).
Among them, Hengrui and China Biopharmaceuticals have been on the list for the third time. In 2019, Hengrui Pharmaceutical ranked 47th with revenue of US$2.570 billion, and ranked 43rd with US$3.321 billion in 2020. Hengrui's ranking continued to climb in 2021, ranking 38th with US$4.203 billion. The three drugs with the highest income are atan, docetaxel and pyrrolidinib.
In recent years, Hengrui Pharmaceutical has always attached great importance to innovative research and development, and R&D investment has increased year by year. In 2020, Hengrui invested 4.989 billion yuan in R&D funds, and R&D investment accounted for 18% of sales, and in the first quarter of 2021, Hengrui Pharmaceutical further increased its investment in innovation, investing 1.316 billion yuan in R&D funds, an increase of 62.26% over the previous year.
In 2021, the newly listed CSPC Pharmaceutical Group's prescription drug revenue was US$3.242 billion, and its annual revenue in 2020 was RMB24.94 billion, an increase of 12.8% year-on-year, and its net profit was RMB5.16 billion, an increase of 38.9% year-on-year. According to the annual report, its main products involve nervous system diseases, anti-tumor, anti-infection, cardiovascular diseases, respiratory diseases, digestive and metabolic diseases and other fields. Neurological disease products and anti-tumor products are the main sources of income.
Enbiprip (butophthalein), kerelli (albumin paclitaxel), and dormecil (doxorubicin hydrochloride) are the main sources of profit contribution for CSPC. Among them, Enbipu, after the medical insurance negotiations to reduce prices, the growth rate of sales revenue in 2020 fell from 36% in 2019 to 17.4%, and the subsequent profit growth rate will also slow down.
CSPC has also focused on the research and development of new drugs in recent years, with R&D expenses of 2.89 billion yuan in 2020, an increase of 44.5% year-on-year. At present, the company's focus areas are mainly small molecule targeted drugs, nanomedicines, monoclonal antibody drugs, dual antibody drugs, antibody conjugated drugs and biological drugs in the field of immunity. There are about 300 projects under research, including more than 40 small molecule innovative drugs, more than 40 large molecule innovative drugs, and more than 20 new formulation agents.
In general, with the high-quality development of the domestic pharmaceutical industry, it is believed that more and more Chinese companies will be listed in the future.
3
The epidemic is the biggest influencing factor
Compared with 2019, 2021 Pharm Exec50 believes that the factor that will have the greatest impact on pharmaceutical companies in 2020 is the new crown epidemic.
According to a survey conducted by Model N, 58 percent of executives said the flu pandemic had a big impact on them. For example, Eli Lilly, Roche, Regeneration And other companies have seen significant market capitalization growth because of the performance of COVID-19 diagnostic testing products. But not all of this has been the case, for example Abb Vie doesn't have any notable COVID products with a year-over-year increase of 44.4%.
However, overall, despite the impact of the new crown, six of the top ten companies in this list have remained unchanged and have not changed much.
Last year, Roche topped the list with sales of $48.247 billion, ending Pfizer's previous four consecutive years of "domination", and this year, despite a 1.6% drop in its prescription drug revenue, it remained in the first place. Avastin remains number one of the three drugs with the best sales performance at Roche, but Ocrevus squeezed Roche's long-term pillar product, Herceptin, which has $4.6 billion in 2020 sales, out of the top three and jumped to second place.
It is understood that the decline in sales of Avastin, Herceptin and Rituxan Troika is due to the impact of biosimilars and the impact of the new crown epidemic, but there are still other products in roche's tumor pipeline. For example, Tecentriq, Perjeta, Kadcyla 3 products, because of the eye-catching performance of sales, are called the new "troika" of Roche's tumor business segment. In addition to the oncology business, blockbuster products such as Ocrevus are an important addition to Roche's product line.
Due to the completion of the acquisition of Allergan in May 2020, AbbVie's volume directly soared from $33.266 billion in 2019 to $45.804 billion, surpassing Pfizer after the divestiture of assets and rising from 8th to 3rd. Currently, Humira remains AbbVie's revenue pillar, contributing $19.832 billion, or about 45 percent of AbbVie's total drug sales, and is one of the largest single drug shares among large pharmaceutical companies.
But Humira will lose global market exclusivity in 2023, and AbbVie wants its next-generation drugs, Skyrizi and Rinvoq, to fill the gap behind the patents. The two drugs were approved to treat psoriasis and rheumatoid arthritis, respectively, with combined sales of $2 billion in 2020. In addition, neurological disease products such as Vraylar (carlirazin), the new migraine drug Uberlvy (ubrogepant), and products such as Imbruvaica (ibrate) and Venclexta (Venacla) in the field of oncology are also expected to become important pillars of future performance.
Overall, some insiders believe that the acquisition of Allergan has greatly enriched AbbVie's product line and got rid of the excessive dependence on Humira in the past.
Attached: 2021 Global Pharmaceutical Companies TOP50 (billion US dollars)
(Image source: Medicine Cube)
This article is copyrighted by Cyberblue (ID: Mic366), unauthorized reproduction is prohibited